Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma

Condition:   Esophageal Squamous Cell Carcinoma
Interventions:   Drug: Anlotinib Plus Irinotecan;   Drug: Irinotecan
Sponsor:   The First Affiliated Hospital of Zhengzhou University
Not yet recruiting

from #ORL via a.lsfakia on Inoreader http://ift.tt/2Cued4c
via IFTTT